Cel Sci (CVM) EPS (Basic) Growth (5y) (2015 - 2026)
Cel Sci (CVM) EPS (Basic) Growth (5y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.40 Bn | 131.55 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.53 Bn | 78.54 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.20 Bn | 60.02 Bn | 1.37 Bn |
| 4 | Moderna | 60.40 Bn | 55.26 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.17 Bn | 37.07 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.36 Bn | 28.05 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.74 Bn | 10.34 Bn | 668.28 Mn |
| 8 | Insmed | 27.45 Bn | 26.29 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.17 Bn | 26.33 Bn | - |
| 10 | Cel Sci | 2.15 Mn | -4.39 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.94% |
| Dec 31, 2025 | 4.66% |
| Sep 30, 2025 | -13.13% |
| Jun 30, 2025 | -3.19% |
| Mar 31, 2025 | -7.79% |
| Dec 31, 2024 | -18.77% |
| Sep 30, 2024 | -17.56% |
| Jun 30, 2024 | 17.56% |
| Mar 31, 2024 | 8.85% |
| Dec 31, 2023 | -38.57% |
| Sep 30, 2023 | 27.87% |
| Jun 30, 2023 | 12.14% |
| Mar 31, 2023 | 9.17% |
| Dec 31, 2022 | 19.06% |
| Sep 30, 2022 | 19.94% |
| Jun 30, 2022 | 15.42% |
| Mar 31, 2022 | 27.68% |
| Dec 31, 2021 | -18.61% |
| Sep 30, 2021 | 2.75% |
| Jun 30, 2021 | 22.09% |